Results 141 to 150 of about 32,676 (224)

TFPIα inhibition by andexanet alfa is partially restored by protein S and factor V-short. [PDF]

Blood Adv
Crossette-Thambiah C, Bamberg K, Laffan M, Ahnström J.   +3 more
europepmc   +1 more source

Venous Thromboembolism in Children: The Rivaroxaban Experience

: The incidence of venous thromboembolism (VTE) in the pediatric population has increased more than 10-fold in the last 20 years, as a consequence of the advancement of resuscitation and surgical techniques and the global increase in life expectancy of ...
Simioni, Paolo, Campello, Elena, Spiezia, Luca, Tormene, Daniela   +3 more
core   +1 more source

Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis. [PDF]

Ren Fail
Wu X, Meng J, Yang Y, Sheng D, Liu X, Zhou Y.   +5 more
europepmc   +1 more source

The application of low-dose rivaroxaban in elderly patients with atrial fibrillation. [PDF]

Front Pharmacol
Wang Z, Dai X, Huang Z, Hu J, Qu J, Wang P, Chen Q, Wang X.   +7 more
europepmc   +1 more source

Enhancing immune response in advanced HCC with PVTT: rivaroxaban as a core adjuvant in combined therapy. [PDF]

J Immunother Cancer
Yan Y, Zou D, Li Y, Ma H, Chen H.
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Emergency reversal of Rivaroxaban with Andexanet alfa in a child with hemorrhagic brain metastasis from Wilms tumor. [PDF]

Childs Nerv Syst
Rafaelian A, Won SY, Mueller L, Armbrust M, Weber KJ, Haas A, Reuter DA, Freiman TM, Gessler F, Spang C, Meyer-Bahlburg A, Hingst P, Classen CF, Dubinski D, Cardesa-Salzmann TM.   +14 more
europepmc   +1 more source

Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in real-world patients with pulmonary embolism in China. [PDF]

Res Pract Thromb Haemost
Ren J, Li Y, Zheng X, Wu Z, Shi J, Han X.   +5 more
europepmc   +1 more source

Oral Anticoagulants and Risk of Bleeding and Death in Cancer-Associated Venous Thromboembolism. [PDF]

JACC Adv
Lutsey PL, Walker RF, Adrianzen-Herrera D, Wang W, Giorgio K, Cogan J, Norby FL, Zakai NA.   +7 more
europepmc   +1 more source